⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20513035 | 0.95 | — | — | |
| SCHEMBL436989 | 0.95 | — | — | |
| SCHEMBL3393452 | 0.81 | — | — | |
| SCHEMBL2780260 | 0.78 | MEN1 (0.32) | — | |
| SCHEMBL634253 | 0.73 | — | — | |
| SCHEMBL9952284 | 0.72 | — | — | |
| SCHEMBL17460346 | 0.72 | — | — | |
| SCHEMBL1397639 | 0.72 | — | — | |
| SCHEMBL15229626 | 0.71 | — | — | |
| SCHEMBL2818899 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117729941-A | Dual amylin and calcitonin receptor agonists and uses thereof | 伊莱利利公司 | 2024-03-19 | — | — | CN | claimed |
| CN-112608377-B | GIP and GLP-1 co-agonist compounds | 伊莱利利公司 | 2024-02-13 | — | — | CN | claimed |
| CN-117402219-A | GLP-1/GIP double agonist and preparation method and application thereof | 杭州中美华东制药有限公司 | 2024-01-16 | — | — | CN | claimed |
| CN-117320740-A | GIP/GLP1 dual agonist treatment methods | 伊莱利利公司 | 2023-12-29 | — | — | CN | claimed |
| US-20230372508-A1 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | OLIX US, INC. | 2023-11-23 | — | — | US | claimed |
| WO-2023225650-A1 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | OLIX US, INC. (US) | 2023-11-23 | — | — | WO | claimed |
| US-20230203558-A1 | DIAGNOSTIC PEPTIDE FOR USE IN A METHOD OF DIAGNOSIS OF VIRAL INFECTION, KIT AND SYSTEM | ORIGINAL G B.V. (NL) | 2023-06-29 | — | — | US | claimed |
| EP-4127206-A1 | DIAGNOSTIC PEPTIDE FOR USE IN A METHOD OF DIAGNOSIS OF VIRAL INFECTION, KIT AND SYSTEM | Original G B.V. (NL) | 2023-02-08 | — | — | EP | claimed |
| CN-115362262-A | Diagnostic peptides for use in methods, kits and systems for diagnosing viral infections | 奥里基诺G有限公司 | 2022-11-18 | — | — | CN | claimed |
| CN-115298207-A | GIP/GLP1 co-agonist compounds | 伊莱利利公司 | 2022-11-04 | — | — | CN | claimed |
| CN-109475592-B | Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease | 伊莱利利公司 | 2022-08-09 | — | — | CN | claimed |
| WO-2021198228-A1 | DIAGNOSTIC PEPTIDE FOR USE IN A METHOD OF DIAGNOSIS OF VIRAL INFECTION, KIT AND SYSTEM | ORIGINAL G B.V. (NL) | 2021-10-07 | — | — | WO | claimed |
| US-9808532-B2 | Peptides whose uptake in cells is controllable | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-07 | — | — | US | claimed |
| US-20120134922-A1 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-31 | — | — | US | claimed |
| US-20120134931-A1 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-31 | — | — | US | claimed |
| EP-2453926-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | The Regents of the University of California (US) | 2012-05-23 | — | — | EP | claimed |
| EP-2454271-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | The Regents of the University of California (US) | 2012-05-23 | — | — | EP | claimed |
| WO-2011008992-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | claimed |
| WO-2011008996-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | claimed |
| US-20240168014-A1 | METHOD FOR THE IN VITRO DIAGNOSIS OF INFECTION | ORIGINAL G B.V. (NL) | 2024-05-23 | — | — | US | disclosed |
| CN-111094331-B | Acylated oxyntomodulin peptide analogues | 东亚ST株式会社 | 2024-03-29 | — | — | CN | disclosed |
| CN-117729941-A | Dual amylin and calcitonin receptor agonists and uses thereof | 伊莱利利公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-117642153-A | Erodible tablet | 伊莱利利公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117597135-A | Application of Mazdutide | 信达生物制药(苏州)有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-112608377-B | GIP and GLP-1 co-agonist compounds | 伊莱利利公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-4308929-A1 | METHOD FOR THE IN VITRO DIAGNOSIS OF INFECTION | Original G B.V. (NL) | 2024-01-24 | — | — | EP | disclosed |
| CN-117402219-A | GLP-1/GIP double agonist and preparation method and application thereof | 杭州中美华东制药有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-117320740-A | GIP/GLP1 dual agonist treatment methods | 伊莱利利公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230372508-A1 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | OLIX US, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023225650-A1 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | OLIX US, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-116940841-A | Methods for in vitro diagnosis of infection | 原始格私人有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116917312-A | Long acting amylin receptor agonists and uses thereof | 伊莱利利公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116854804-A | Acylated oxyntomodulin peptide analogues | 东亚ST株式会社 | 2023-10-10 | — | — | CN | disclosed |
| CN-110741242-B | Ratio fluorescence imaging method | 艾维拉斯生物科学公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20230203558-A1 | DIAGNOSTIC PEPTIDE FOR USE IN A METHOD OF DIAGNOSIS OF VIRAL INFECTION, KIT AND SYSTEM | ORIGINAL G B.V. (NL) | 2023-06-29 | — | — | US | disclosed |
| EP-4127206-A1 | DIAGNOSTIC PEPTIDE FOR USE IN A METHOD OF DIAGNOSIS OF VIRAL INFECTION, KIT AND SYSTEM | Original G B.V. (NL) | 2023-02-08 | — | — | EP | disclosed |
| CN-115362262-A | Diagnostic peptides for use in methods, kits and systems for diagnosing viral infections | 奥里基诺G有限公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-115298207-A | GIP/GLP1 co-agonist compounds | 伊莱利利公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20220288223-A1 | ACTIVATABLE SPECIFIC BINDING MEMBER COMPLEXES, AND METHODS OF MAKING AND USING SAME | CALIFORNIA, THE REGENTS OF THE UNIVERSITY OF | 2022-09-15 | — | — | US | disclosed |
| CN-114981295-A | Polypeptide compound and application thereof | 联邦生物科技(珠海横琴)有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-109475592-B | Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease | 伊莱利利公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-114787183-A | Incretin analogue and application thereof | 伊莱利利公司 | 2022-07-22 | — | — | CN | disclosed |
| US-11246940-B2 | Peptides whose uptake in cells is controllable | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-15 | — | — | US | disclosed |
| WO-2021198228-A1 | DIAGNOSTIC PEPTIDE FOR USE IN A METHOD OF DIAGNOSIS OF VIRAL INFECTION, KIT AND SYSTEM | ORIGINAL G B.V. (NL) | 2021-10-07 | — | — | WO | disclosed |
| EP-3876196-A1 | RATIOMETRIC FLUORESCENCE IMAGING METHODS | Avelas Biosciences, Inc. (US) | 2021-09-08 | — | — | EP | disclosed |
| US-11052160-B2 | Selective delivery molecules and methods of use | AVELAS BIOSCIENCES, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| CN-112469731-A | GIP/GLP1 co-agonist compounds | 伊莱利利公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20200376013-A1 | SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE | AVELAS BIOSCIENCES, INC. | 2020-12-03 | — | — | US | disclosed |
| WO-2020186090-A2 | ACTIVATABLE SPECIFIC BINDING MEMBER COMPLEXES, AND METHODS OF MAKING AND USING SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-17 | — | — | WO | disclosed |
| US-20200150041-A1 | RATIOMETRIC FLUORESCENCE IMAGING METHODS | AVELAS ACQUISITION CORPORATION | 2020-05-14 | — | — | US | disclosed |
| US-10596259-B2 | Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-03-24 | — | — | US | disclosed |
| CN-105102484-B | Selective delivery molecules and methods of use | 艾维拉斯生物科学公司 | 2020-03-10 | — | — | CN | disclosed |
| US-10570178-B2 | Selective delivery molecules and methods of use | AVELAS BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| EP-3610243-A1 | RATIOMETRIC FLUORESCENCE IMAGING METHODS | Avelas Biosciences, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| US-20200046843-A1 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-13 | — | — | US | disclosed |
| CN-110741242-A | Ratiometric fluorescence imaging method | 艾维拉斯生物科学公司 | 2020-01-31 | — | — | CN | disclosed |
| US-20190321496-A1 | AGENTS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH EXTRACELLULAR MATRIX TURNOVER | BAKER IDI HEART AND DIABETES INSTITUTE HOLDINGS LIMITED (AU) | 2019-10-24 | — | — | US | disclosed |
| US-10385380-B2 | Personalized protease assay to measure protease activity in neoplasms | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-20 | — | — | US | disclosed |
| CN-109922817-A | The agent and method of relevant disease are had enough to meet the need to extracellular matrix for diagnosing and treating | 贝克IDI心脏和糖尿病研究院控股有限公司 | 2019-06-21 | — | — | CN | disclosed |
| US-20190175021-A1 | IMAGING SYSTEM AND METHOD FOR FLUORESCENCE GUIDED SURGERY | UNIV CALIFORNIA (US) | 2019-06-13 | — | — | US | disclosed |
| US-20190151481-A1 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE | AVELAS ACQUISITION CORPORATION | 2019-05-23 | — | — | US | disclosed |
| US-20190119327-A1 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE | AVELAS ACQUISITION CORPORATION | 2019-04-25 | — | — | US | disclosed |
| EP-3471748-A1 | AGENTS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH EXTRACELLULAR MATRIX TURNOVER | Baker IDI Heart and Diabetes Institute Holdings Ltd (AU) | 2019-04-24 | — | — | EP | disclosed |
| EP-3473273-A1 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE | Avelas Biosciences, Inc. (US) | 2019-04-24 | — | — | EP | disclosed |
| US-10239919-B2 | Selective delivery molecules and methods of use | AVELAS BIOSCIENCES, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10231626-B2 | Imaging system and method for fluorescence guided surgery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-03-19 | — | — | US | disclosed |
| US-10226539-B2 | Selective delivery molecules and methods of use | AVELAS BIOSCIENCES, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10202422-B2 | — | — | 2019-02-12 | — | — | US | disclosed |
| WO-2018187629-A1 | RATIOMETRIC FLUORESCENCE IMAGING METHODS | AVELAS BIOSCIENCES, INC. (US) | 2018-10-11 | — | — | WO | disclosed |
| US-10029017-B2 | Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2736533-B1 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE | AVELAS BIOSCIENCES INC (US) | 2018-07-04 | — | — | EP | disclosed |
| US-20180140703-A1 | TUMOR RADIOSENSITIZATION WITH ANTIBODY CONJUGATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-05-24 | — | — | US | disclosed |
| US-20180057536-A1 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE | AVELAS ACQUISITION CORPORATION | 2018-03-01 | — | — | US | disclosed |
| US-20180000971-A1 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE | AVELAS ACQUISITION CORPORATION | 2018-01-04 | — | — | US | disclosed |
| WO-2017214681-A1 | AGENTS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH EXTRACELLULAR MATRIX TURNOVER | BAKER IDI HEART AND DIABETES INSTITUTE HOLDINGS LIMITED (AU) | 2017-12-21 | — | — | WO | disclosed |
| US-9840537-B2 | Selective delivery molecules and methods of use | AVELAS BIOSCIENCES, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9808532-B2 | Peptides whose uptake in cells is controllable | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170305968-A1 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-10-26 | — | — | US | disclosed |
| US-9782498-B2 | Selective delivery molecules and methods of use | AVELAS BIOSCIENCES, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9682151-B2 | Peptides whose uptake in cells is controllable | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170080088-A1 | TUMOR RADIOSENSITIZATION WITH MONOMETHYL AURISTATIN E (MMAE) AND DERIVATIVES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-23 | — | — | US | disclosed |
| US-20170044214-A1 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE | AVELAS ACQUISITION CORPORATION | 2017-02-16 | — | — | US | disclosed |
| US-9504763-B2 | Selective delivery molecules and methods of use | AVELAS BIOSCIENCES, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| CN-103874512-B | Selectively deliver molecule and using method | 艾维拉斯生物科学公司 | 2016-11-16 | — | — | CN | disclosed |
| US-20160220707-A1 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE | AVELAS ACQUISITION CORPORATION | 2016-08-04 | — | — | US | disclosed |
| US-9371367-B1 | Selective delivery molecules and methods of use | AVELAS BIOSCIENCES, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20160160263-A1 | PERSONALIZED PROTEASE ASSAY TO MEASURE PROTEASE ACTIVITY IN NEOPLASMS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-06-09 | — | — | US | disclosed |
| US-20160152670-A1 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE | AVELAS ACQUISITION CORPORATION | 2016-06-02 | — | — | US | disclosed |
| US-20160082119-A1 | SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE | AVELAS BIOSCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| US-9278144-B2 | Selective delivery molecules and methods of use | AVELAS BIOSCIENCES, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2988786-A1 | SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE | Avelas Biosciences, Inc. (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20150359902-A1 | PRETARGETED ACTIVATABLE CELL PENETRATING PEPTIDE WITH INTRACELLULARLY RELEASABLE PRODRUG | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-17 | — | — | US | disclosed |
| US-20150359908-A1 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE | AVELAS ACQUISITION CORPORATION | 2015-12-17 | — | — | US | disclosed |
| EP-2951210-A1 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE | Avelas Biosciences, Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014120837-A9 | PRETARGETED ACTIVATABLE CELL PENETRATING PEPTIDE WITH INTRACELLULARY RELEASEABLE PRODRUG | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20150031852-A1 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE | AVELAS BIOSCIENCES, INC. (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2014176284-A1 | SELECTIVE DRUG DELIVERY COMPOSITIONS AND METHODS OF USE | AVELAS BIOSCIENCES, INC. (US) | 2014-10-30 | — | — | WO | disclosed |
| US-20140276008-A1 | IMAGING SYSTEM AND METHOD FOR FLUORESCENCE GUIDED SURGERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014120837-A2 | PRETARGETED ACTIVATABLE CELL PENETRATING PEPTIDE WITH INTRACELLULARY RELEASEABLE PRODRUG | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014120974-A1 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE | AVELAS BIOSCIENCES, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| EP-2736533-A2 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE | Avelas Biosciences, Inc. (US) | 2014-06-04 | — | — | EP | disclosed |
| WO-2013019681-A2 | SELECTIVE DELIVERY MOLECULES AND METHODS OF USE | AVELAS BIOSCIENCES, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20120134922-A1 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120134931-A1 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2453926-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | The Regents of the University of California (US) | 2012-05-23 | — | — | EP | disclosed |
| EP-2454271-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | The Regents of the University of California (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011008992-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011008992-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011008996-A2 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-20 | — | — | WO | disclosed |